Oligopeptide-1 (EGF)

Oligopeptide-1, often labeled sh-oligopeptide-1, is the cosmetic ingredient name for epidermal growth factor. EGF is a 53-amino-acid human protein, larger than many skincare peptides. The “sh” prefix means synthetic human: recombinant microbes, yeast or plants produce it rather than extraction from people.

EGF binds its receptor on skin cells, triggering keratinocyte and fibroblast proliferation, migration and renewal. Experimental work links this signaling to collagen, elastin and other matrix components involved in skin appearance.

How much of this relatively large protein crosses intact outer skin remains debated, making delivery a significant formulation challenge. Mechanistic activity does not establish the performance of a finished serum.

Serums marketed for regeneration or repair use it for the appearance of fine lines, texture, firmness and elasticity, and for comfort or recovery after cosmetic procedures. Combination formulas are common.

FDA does not preapprove cosmetic ingredients. Appearance claims belong to a different category from claims to heal wounds or alter body structure/function, which would make a product a drug. Cosmetic ingredient status is not approval of EGF as a therapeutic medicine.

A small short pilot randomized trial comparing recombinant-EGF serum with another EGF serum found investigator-rated texture and firmness improvement, with little wrinkle change. Other studies use multicomponent regimens, preventing isolation of EGF’s contribution. No large independent trial or meta-analysis establishing standalone topical-EGF wrinkle efficacy is described.

Small studies report good tolerability, but evidence is limited. Its growth-signaling biology warrants caution on compromised skin or with a personal skin-cancer history. Cosmetic studies have not demonstrated adverse growth effects, which is not the same as extensive long-term safety evidence. Sensitive skin may benefit from patch testing.